ReviewClinical & developmental immunology2012
Invariant NKT cells as novel targets for immunotherapy in solid tumors.
Review in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Natural Killer T Cell Function in Lymphoma Patients.Biomolecules · 2026Article
- Interplay between innate-like T-cells and microRNAs in cancer immunity.Discover oncology · 2025Review
- Optimizing iNKT-driven immune responses against cancer by modulating CD1d in tumor and antigen presenting cells.Clinical immunology (Orlando, Fla.) · 2024Review
- Proteomic profiling and biomarker discovery for predicting the response to PD-1 inhibitor immunotherapy in gastric cancer patients.Frontiers in pharmacology · 2024Article
- Advances and challenges of CAR T therapy and suitability of animal models (Review).Molecular and clinical oncology · 2022Review
- Sterile activation of invariant natural killer T cells by ER-stressed antigen-presenting cells.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Evolutionary Underpinnings of Innate-Like T Cell Interactions with Cancer.Immunological investigations · 2019Review
- Natural killer T cell activation increases iNOSJournal for immunotherapy of cancer · 2019Article
- Macrophage Transactivation for Chemokine Production Identified as a Negative Regulator of Granulomatous Inflammation Using Agent-Based Modeling.Frontiers in immunology · 2018Article
- Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.Translational research : the journal of laboratory and clinical medicine · 2017Review
- Tumor immunology viewed from alternative animal models-theCurrent pathobiology reports · 2017Article
- Natural Killer T Cells in Cancer Immunotherapy.Frontiers in immunology · 2017Review
- Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.Frontiers in oncology · 2015Review
- The immunological synapse.Cancer immunology research · 2014Review
- A critical role of non-classical MHC in tumor immune evasion in the amphibian Xenopus model.Carcinogenesis · 2014Article
- Percentages of NKT cells in the tissues of patients with non-small cell lung cancer who underwent surgical treatment.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2014Article
- Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes.Journal for immunotherapy of cancer · 2014Article
- Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.PloS one · 2013Article
- Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer.Cancers · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Natural killer T (NKT) cells are a small population of lymphocytes that possess characteristics of both innate and adaptive immune cells. They are uniquely poised to respond rapidly to infection and inflammation and produce cytokines that critically shape the ensuing adaptive cellular response. Therefore, they represent promising therapeutic targets. In cancer, NKT cells are attributed a role in immunosurveillance. NKT cells also act as potent activators of antitumor immunity when stimulated with a synthetic agonist in experimental models. However, in some settings, NKT cells seem to act as suppressors and regulators of antitumor immunity. Here we briefly review current data supporting these paradoxical roles of NKT cells and their regulation. Increased understanding of the signals that determine the function of NKT cells in cancer will be essential to improve current strategies for NKT-cell-based immunotherapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.